Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Shaw Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Battling Blood-Sucking Bugs
      • Unexpected Leads to Curb Addiction
      • Shaping Therapies for Sickle Cell Disease
      • The Mind’s Map Maker
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
I am Intramural Blog

Creating Cutting-Edge Cancer Vaccines

IRP Research Identifies a Tantalizing Target for Cancer Immunotherapy

By Melissa Glim

Wednesday, February 1, 2023

person getting vaccine injection

Research led by IRP senior investigator Claudia Palena could lead to vaccines that help the immune system fight off cancer.

February 4 is World Cancer Day, a time to mark international efforts to prevent, detect, and treat cancer. Immunotherapy, one of the most significant advances in treating cancer, was pioneered here at NIH more than 30 years ago. Today, IRP senior investigator Claudia M. Palena, Ph.D., is pushing cancer immunotherapy forward with the discovery of a novel target for cancer vaccines.

Immunotherapy treatments for cancer, including cancer vaccines, harness the body’s own defenses to detect and kill any cells deemed foreign or abnormal, including tumor cells. Unlike vaccines against viruses, which prevent infection, cancer vaccines provoke the immune system to recognize and attack molecules found on tumors, including proteins that are more abundant on cancer cells and that may help them grow and spread through the body, a process called metastasis.

Dr. Palena’s research team discovered a protein that plays a key role in tumors’ ability to metastasize and become resistant to standard therapies like chemotherapy and radiation. The molecule, called T-box transcription factor brachyury, is a protein that was long thought to exist only on cells that are part of a developing embryo. However, Dr. Palena’s IRP team found abnormally high levels of brachyury in the cancer cells of adults with various types of carcinoma, a cancer that arises from the ‘epithelial’ cells that line most organs and the skin. The researchers found brachyury not just in the original tumor, but also in metastatic tumors that had spread from the original site to multiple other organs. By contrast, in normal, healthy tissue, the molecule was mostly absent.

“One of the challenges we faced when we started was that very little was known about brachyury,” says Dr. Palena. “We knew it played a role in embryonic development, but we didn’t know what role, if any, this molecule was playing in a cancer cell.”

Dr. Claudia Palena

Dr. Claudia Palena

The brachyury protein, it turns out, plays a key role in driving a process called the ‘epithelial-to-mesenchymal transition,’ or EMT.1 During early embryonic development, epithelial cells transform into mesenchymal cells, which have the capacity to further develop into multiple types of more mature cells, including connective tissue, blood vessels, and disease-fighting white blood cells. However, the EMT can also occur in carcinoma cells, granting them the ability to move throughout the body and become resistant to treatment. Dr. Palena’s team discovered that when the original, or 'primary,’ tumor that appeared in a patient’s body has high levels of brachyury, that patient is more likely to have a poor clinical outcome. This led her to theorize that targeting a protein like brachyury that regulates the EMT may be a valuable approach for a cancer vaccine.

“Our main drive and interest in studying brachyury was functional: by learning about its role, we became really interested in how it contributes to changes in tumor characteristics,” Dr. Palena says. “It’s different from other potential vaccine targets that are just over-abundant in cancer cells because brachyury also plays an important role in making tumors more aggressive.”

killer T cells surrounding a cancer cell

Killer T cells surround a cancer cell. These T cells attach to and spread over their target, then use special chemicals (red) to deliver a killing blow. Image credit: Alex Ritter, Jennifer Lippincott Schwartz, and Gillian Griffiths

This effort has already born fruit. Dr. Palena’s team showed that immune cells called T cells that have been isolated from a cancer patient’s blood can attack tumor cells that carry the brachyury protein.2 In addition, through collaborations with other groups of researchers both within and outside NIH, her team has contributed to the development of three brachyury-based cancer vaccines, which have already begun testing in Phase I and II clinical trials in patients with advanced cancers, including those with a rare type of tumor called a chordoma that appears in the spine or at the base of the skull.

Ultimately, Dr. Palena hopes that using cancer vaccines in combination with other cancer-fighting therapies could greatly improve outcomes for patients. To help bring that vision into reality, her laboratory is also studying molecules that are secreted in large amounts by cells that over-produce brachyury. Her team has already demonstrated that one of those molecules, interleukin-8, plays a role in making tumors more aggressive and might be a useful additional target to improve cancer immunotherapy.3

If her efforts are successful, Dr. Palena says, it will be in large part due to the opportunities NIH provides to work with different groups in the IRP, including the NIH Clinical Center and Tech Transfer Office, which has helped her team form collaborative relationships both within NIH and with outside biotech companies.

“The NIH is a highly collaborative environment, and this work is really a team science effort,” Dr. Palena says. “That was essential.”

Subscribe to our weekly newsletter to stay up-to-date on the latest breakthroughs in the NIH Intramural Research Program.

References:

[1] Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest. 2010;120(2):533-44. doi: 10.1172/JCI38379.

[2] Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res. 2007 Apr 15;13(8):2471-8. doi: 10.1158/1078-0432.CCR-06-2353.

[3] Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011;71(15):5296-306. doi: 10.1158/0008-5472.CAN-11-0156.


Category: IRP Discoveries
Tags: cancer, tumor, tumors, carcinoma, immunotherapy, immune system, vaccine, vaccines

Related Blog Posts

  • IRP Research Yields Life-Changing Treatments
  • A Ray of Hope for a Rare and Deadly Skin Cancer
  • Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer
  • Dying Tumor Cells Suppress Anti-Cancer Immune Response
  • Leveraging Turncoat Immune Cells to Combat Cancer

This page was last updated on Tuesday, May 23, 2023

Blog menu

  • Contributing Authors
    • Anindita Ray
    • Brandon Levy
    • Devon Valera
    • Melissa Glim
  • Categories
    • IRP Discoveries
    • Profiles
    • Events
    • NIH History
    • IRP Life

Blog links

  • Subscribe to RSS feed

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search